Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231391 | 0.89 | EGFR (0.53) | EGFRKDM4EALDH1A1MEN1HPGD | |
| SCHEMBL5235585 | 0.85 | EGFR (0.56) | EGFRKDM4EALDH1A1MEN1HPGD | |
| SCHEMBL3271808 | 0.84 | MIF (0.45) | EGFRALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL4864274 | 0.84 | MIF (0.45) | EGFRALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL5232777 | 0.84 | TGFBR1 (0.46) | EGFRKDM4EALDH1A1MEN1HPGD | |
| SCHEMBL13860649 | 0.82 | EGFR (0.78) | EGFRKDM4EALDH1A1MEN1HPGD | |
| SCHEMBL5235429 | 0.81 | ALDH1A1 (0.44) | EGFRKDM4EALDH1A1MEN1HPGD | |
| SCHEMBL5234607 | 0.81 | TGFBR1 (0.43) | EGFRKDM4EALDH1A1GAATGFBR1 | |
| SCHEMBL1780786 | 0.79 | EGFR (0.53) | EGFRKDM4EALDH1A1MEN1HPGD | |
| SCHEMBL956204 | 0.79 | EGFR (0.55) | EGFRKDM4EALDH1A1MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | disclosed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | TGFB2, TGFB1, TGFBR1 | EGFR 1392/4885KDM4E 4041/4885ALDH1A1 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.